Please assess the completion status of the following clinical trial:

Trial Title: The Treatment of Glabellar Frown Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient females 18 to 50 years of age~* Moderate to severe glabellar frown lines~Exclusion Criteria:~* Glabellar Frown Lines at rest rating 3 on the 4-point Facial Wrinkle Scale~* Previous treatment with botulinum toxin~* Previous treatment with biodegradable fillers in glabellar area within last 12 months~* Any severe or uncontrolled systemic disease, malignant tumor, or medical history of HIV infection~* Known hypersensitivity to incobotulinumtoxinA or onabotulinumtoxinA or to any of their excipients~* Intake of any of the forbidden concomitant medication or other agents that might interfere with neuromuscular function or might interfere with the action of botulinum toxin type within 14 days prior to injection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Type: EXPERIMENTAL): 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
- OnabotulinumtoxinA (Type: ACTIVE_COMPARATOR): 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points

Based on this trial design, predict the completion outcome and termination type (if applicable).